Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) Common Equity (2016 - 2025)

Cellectis (CLLS) has 8 years of Common Equity data on record, last reported at $118.0 million in Q4 2022.

  • For Q4 2022, Common Equity fell 46.69% year-over-year to $118.0 million; the TTM value through Dec 2022 reached $118.0 million, down 46.69%, while the annual FY2022 figure was $118.0 million, 46.69% down from the prior year.
  • Common Equity reached $118.0 million in Q4 2022 per CLLS's latest filing, down from $221.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $409.3 million in Q4 2018 and bottomed at $118.0 million in Q4 2022.
  • Average Common Equity over 4 years is $258.1 million, with a median of $252.5 million recorded in 2020.
  • Peak YoY movement for Common Equity: surged 44.13% in 2018, then plummeted 46.69% in 2022.
  • A 4-year view of Common Equity shows it stood at $409.3 million in 2018, then tumbled by 30.66% to $283.8 million in 2020, then decreased by 22.02% to $221.3 million in 2021, then tumbled by 46.69% to $118.0 million in 2022.
  • Per Business Quant database, its latest 3 readings for Common Equity were $118.0 million in Q4 2022, $221.3 million in Q4 2021, and $283.8 million in Q4 2020.